Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
1. A compound selected from the group consisting of:
wherein sites designated as D contain deuterium enrichment of at least 1%;
or a pharmaceutically acceptable salt thereof.
2. The compound as recited in claim 1 , wherein said compound is the R-enantiomer.
3. The compound as recited in claim 1 , wherein said compound is the S-enantiomer.
4. The compound as recited in claim 1 , wherein said compound is a hydrochloride salt.
5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition as recited in claim 5 , formulated as a tablet or capsule.
7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 2 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 3 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 4 and a pharmaceutically acceptable carrier.
10. The compound as recited in claim 1 wherein said compound is a mixture of enantiomers.
11. The compound as recited in claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 10%.
12. The compound as recited in claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 20%.
13. The compound as recited in claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 50%.
14. The compound as recited in claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 70%.
15. The compound as recited in claim 1 , wherein sites designated as D contain deuterium enrichment of greater than 90%.
16. The compound as recited in claim 1 , comprising about 10% or less by weight of the S-enantiomer.
17. The compound as recited in claim 1 , comprising about 10% or less by weight of the R-enantiomer.